Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
PYC Therapeutics reports positive early-stage trial results for VP-001, an investigational drug targeting Retinitis Pigmentosa type 11 (RP11), with some patients showing vision improvements.
PYC Therapeutics reports that repeat doses of VP-0014 in RP11 patients sustain the vision improvements initially seen with a single dose.
PYC Therapeutics has been granted Orphan Drug Designation by the FDA for VP-001, a drug candidate targeting Retinitis Pigmentosa type 11 (RP11).